Advances in the development of novel analgesics

Bibliography

• Shieh C-C, Jarvis MF, Lee C-H, et al. P2x receptor ligands and pain. Expert Opin Ther Patents 2006;16:1113-1127.
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories, USA. WO2002094767; 2002
   Google Scholar
• Astellas Pharma, Inc., Japan. WO2005072746; 2005
   Google Scholar
• Roche Palo Alto LLC, USA. US2005209260; 2005
   Google Scholar
• Roche Palo Alto LLC, USA. US2007049609; 2007
   Google Scholar
• Roche Palo Alto LLC, USA. US2007049758; 2007
   Google Scholar
• Roche Palo Alto LLC, USA. US2007037974; 2007
   Google Scholar
• Bayer Healthcare AG, Germany. DE10312969; 2004
   Google Scholar
• Nippon Chemiphar Co., Ltd., Japan, Hirate, Takako. WO2007074940; 2007
   Google Scholar
• Nippon Chemiphar Co., Ltd., Japan, Hirate, Takako. WO2007072974; 2007
   Google Scholar
• Kyushu University, National University Corporation, Japan. WO2007049825; 2007
   Google Scholar
• Renovis, Inc., USA. WO2006102610; 2006
   Google Scholar
• Renovis, Inc., USA. WO2006102588; 2006
   Google Scholar
• Renovis, Inc., USA. WO2007109182; 2007
   Google Scholar
• Renovis, Inc., USA. WO2007109201; 2007
   Google Scholar
• Abbott Laboratories, USA. WO2006086229; 2006
   Google Scholar
• Abbott Laboratories, USA. WO2007056091; 2007
   Google Scholar
• Nelson DW, Gregg RJ, Kort ME, et al. Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2x7 antagonists. J Med Chem 2006;49:3659-66
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories, USA. WO2006110516; 2006
   Google Scholar
• Bayer Healthcare AG, Germany. WO2005019182; 2005
   Google Scholar
• Okuhara DY, Hsia AY, Xie M. Transient receptor potential channels as drug targets. Expert Opin Ther Targets 2007;11:391-401
   PubMed Web of Science ®Google Scholar
• Cortright DN, Krause JE, Broom DC. Trp channels and pain. Biochem Biophys Acta 2007;1772:978-88
   PubMed Web of Science ®Google Scholar
• Levine JD, Alessandri-Haber N. Trp channels: targets for the relief of pain. Biochem Biophys Acta 2007;1772:989-1003
   PubMed Web of Science ®Google Scholar
• Tominaga M. Nociception and Trp channels. Handb Exp Pharmacol 2007;179:489-505
   Google Scholar
• Appendino G, Ech-Chalad A, Minassi A, et al. Structure-activity relationships of the ultrapotent vanilloid resiniferatixin (Rtx): the homovanillyl moiety. Bioorg Med Chem Lett 2007;17:132-5
   PubMedGoogle Scholar
• Szallasi A, Cortright DN, Blum CA, Eid SR. The vanilloid receptor Trpv: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 2007;6:357-72
   PubMed Web of Science ®Google Scholar
• Westaway SM. The potential of transient receptor potential vanilloid type 1 channel modulators for treatment of pain. J Med Chem 2007;50:2589-96
   PubMed Web of Science ®Google Scholar
• Gunthorpe MJ, Rami HK, Jerman JC, et al. Identification and characterisation of Sb-366791, a potent and selective vanilloid receptor (Vr1/Trpv1) antagonist. Neuropharmacology 2004;46:133-49
   PubMed Web of Science ®Google Scholar
• Varga A, Nemeth J, SZABO A, et al. Effects of the novel Trpv1 receptor antagonist Sb366791 in vitro and in vivo in the rat. Neurosci Lett 2005;385:137-42
   PubMed Web of Science ®Google Scholar
• Doherty EM, Fotsch C, Bannon AW, et al. Novel vanilloid receptor-1 antagonists. 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate. J Med Chem 2007;50:3515-27
   PubMed Web of Science ®Google Scholar
• Gavva NR, Bannon AW, Hovland DN, et al. Repeated administration of vanilloid receptor Trpv1 antagonists attenuates hyperthermia elicited by Trpv1 blockade. J Pharmacol Exp Ther 2007;323:128-37
   PubMed Web of Science ®Google Scholar
• Wang H-L, Katon J, Balan C, et al. Novel vanilloid receptor-1 antagonists. 3. The identification of a second generation clinical candidate with improved physicochemical and pharmacokinetic properties. J Med Chem 2007;50:3528-39
   PubMed Web of Science ®Google Scholar
• Lehto S, Tamir R, Deng H, et al. Antihyperalgesic effects of Amg8562, a novel vanilloid receptor Trpv1 modulator that does not cause hyperthermia in rats. J Pharmacol Exp Ther 2008; Epub ahead of print
   PubMedGoogle Scholar
• Gunthorpe MJ, Hannan SL, Smart D, et al. Characterization of Sb-705498, a potent and selective vanilloid receptor-1 (Vr1/Trpv1) antagonist that inhibits the capsaicin-, acid- and heat-mediated activation of the receptor. J Pharmacol Exp Ther 2007;321:1183-92
   PubMed Web of Science ®Google Scholar
• Chizh BA, O'Donnell MB, Napolitano A, et al. The effects of the Trpv1 antagonist Sb-705498 on Trpv1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 2007;132:132-41
   PubMed Web of Science ®Google Scholar
• Correll CC, Palani A. Advances in the development of Trpv1 antagonists. Expert Opin Ther Patents 2006;16:783-95
   Web of Science ®Google Scholar
• Kyle DJ, Tafesse L. Trpv1 antagonists: a survey of the patent literature. Expert Opin Ther Patents 2006;16:977-96
   Web of Science ®Google Scholar
• Wang X, Chakrabarti PP, Ognyanov VI, et al. Trisubstituted pyrimidines as transient receptor potential vanilloid 1 (Trpv1) antagonists with improved solubility. Bioorg Med Chem Lett 2007;17:6539-45
   PubMedGoogle Scholar
• Gore VK, Ma VV, Tamir R, et al. Structure-activity relationship (Ar) investigations of substituted imidazole analogs as Trpv1 antagonists. Bioorg Med Chem Lett 2007;17:5825-30
   PubMedGoogle Scholar
• Viswanadhan VN, Sun Y, Norman MH. Three-dimensional quantitative structure-activity relationships and activity predictions of human Trpv1 channel antagonists: comparative molecular field analysis and comparative milecular similarity index analysis of cinnamides. J Med Chem 2007;50:5608-19
   PubMedGoogle Scholar
• Drizin I, Gomtsyan A, Bayburt EK, et al. Structure-activity studies of a novel series of 5,6-fused heteroaromatic ureas as Trpv1 antagonists. Bioorg Med Chem 2006;14:4740-9
   PubMedGoogle Scholar
• Perner RJ, Didomenico, Koenig JR, et al. In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists. J Med Chem 2007;50:3651-60
   PubMedGoogle Scholar
• Gomtsyan A, Bayburt EK, Keddy R, et al. A-methylation at benzylic fragment of N-Aryl-N′-benzyl ureas provides Trpv1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model. Bioorg Med Chem Lett 2007;17:3894-9
   PubMedGoogle Scholar
• Jetter MC, Youngman MA, McNally JJ, et al. Heteroaryl B-tetralin ureas as novel antagonist of human Trpv1. Bioorg Med Chem Lett 2007;17:6160-3
   PubMedGoogle Scholar
• Westaway SM, Chung Y-K, Davis JB, et al. N-tetrahydroquinolyl, N-quinolyl and N-isoquinolyl biaryl carboxamides as antagonists of Trpv1. Bioorg Med Chem Lett 2006;16:4533-6
   PubMedGoogle Scholar
• Zheng X, Hodgetts KJ, Brielmann H, et al. From arylureas to bearylamides to aminoquinazolines: discovery of a novel, potent Trpv1 antagonist. Bioorg Med Chem Lett 2006;16:5217-21
   PubMed Web of Science ®Google Scholar
• Kang DW, Ryu H, Lee J, et al. Halogenation of 4-hydroxy-3-methoxybenzyl thiourea Trpv1 agonists showed enhanced antagonism of capsaicin. Bioorg Med Chem Lett 2007;17:214-9
   PubMedGoogle Scholar
• Ryu H, Kim SY, Choi H-K, et al. Stereospecific high-affinity Trpv1 antagonists: chiral n-(2-benzyl-3-pivaloyloxypropyl) 2-[4-(methylsulfonylamino)phenyl]propiamide analogues. J Med Chem 2008;51:57-67
   PubMedGoogle Scholar
• Chung J-U, Kim SY, Lim J-O, et al. A-substituted N-(4-tert-butylbenzyl)-N′-[4-(methylsulfonylamino)-benzyl]thiourea analogues as potent and specific trpv1 antagonists. Bioorg Med Chem 2007;15:6043-53
   PubMed Web of Science ®Google Scholar
• Tang L, Chen Y, Blumbert PM, et al. Antinociceptive pharmacology of N-(4-chlorobenzyl)-N′-(4-hydroxy-3-iodo-5-methoxybenzyl) thiourea, a high-affinity competitive antagonist of the transient receptor potential vanilloid 1 receptor. J Pharmacol Exp Ther 2007;321:7791-8
   Google Scholar
• Ortar G, Cascio MG, De Petrocellis L, et al. New N-arachidonoylserotonin analogs with potential “Dual” mechanism of action. J Med Chem 2007;50:6554-69
   PubMedGoogle Scholar
• Quintanar-Audelo M, Fernandez-Carajal A, Van Den Nest W, et al. Design and synthesis of indole-based peptoids as potential noncompetitive antagonist of transient receptor potential vanilloid 1. J Med Chem 2007;50:6133-43
   PubMedGoogle Scholar
• Painceptor Pharma Corporation, Can. WO2007115403; 2007
   Google Scholar
• Painceptor Pharma Corporation, Can. WO2007115408; 2007
   Google Scholar
• Painceptor Pharma Corporation, Can. WO2007115410; 2007
   Google Scholar
• Amphora Discovery Corporation, USA. WO2007067756; 2007
   Google Scholar
• Amphora Discovery Corporation, USA. WO2007067710; 2007
   Google Scholar
• Amphora Discovery Corporation, USA. WO2007067711; 2007
   Google Scholar
• Ambergen, Inc., USA. WO2007067719; 2007
   Google Scholar
• Novartis AG, Switz.; Novartis Pharma GmbH. WO2007065662; 2007
   Google Scholar
• Novartis AG, Switz.; Novartis Pharma GmbH. WO2007065663; 2007
   Google Scholar
• Novartis AG, Switz.; Novartis Pharma GmbH. WO2007065888; 2007
   Google Scholar
• Mochida Pharmaceutical Co., Ltd., Japan. WO2007010383; 2007
   Google Scholar
• AstraZeneca AB, Swed. WO2007091946; 2007
   Google Scholar
• AstraZeneca AB, Swed. WO2007091948; 2007
   Google Scholar
• Abbott Laboratories, USA. WO2007050732; 2007
   Google Scholar
• Abbott Laboratories, USA. WO2007121299; 2007
   Google Scholar
• NV Organon, Neth. WO2007054474; 2007
   Google Scholar
• NV Organon, Neth. WO2007054480; 2007
   Google Scholar
• Pfizer Japan, Inc., Japan; Pfizer, Inc. WO2007129188; 2007
   Google Scholar
• Astellas Pharma, Inc., Japan. WO2007063925; 2007
   Google Scholar
• sanofi-aventis, Fr. WO2007010138; 2007
   Google Scholar
• sanofi-aventis, Fr. WO2007010144; 2007
   Google Scholar
• Janssen Pharmaceutica NV, Belg. US2008004253; 2008
   Google Scholar
• The Cleveland Clinic Foundation. US2007259936; 2007
   Google Scholar
• AstraZeneca AB, Swed. US2007185179; 2007
   Google Scholar
• AstraZeneca AB, Swed. WO2007073303; 2007
   Google Scholar
• Amorepacific Corporation, S. Korea. EP1862454; 2007
   Google Scholar
• Amorepacific Corporation, S. Korea. WO2007120012; 2007
   Google Scholar
• Janssen Pharmaceutica NV, Belg. WO2007109355; 2007
   Google Scholar
• Renovis, Inc., USA. WO2007100758; 2007
   Google Scholar
• Renovis, Inc., USA, Pfizer, Inc. WO2007133637; 2007
   Google Scholar
• sanofi-aventis, Fr. WO2007088277; 2007
   Google Scholar
• Glenmark Pharmaceuticals SA, Switz. WO2007042906; 2007
   Google Scholar
• Japan Tobacco, Inc., Japan. US2007149517; 2007
   Google Scholar
• Shionogi & Co., Ltd., Japan. WO2007069773; 2007
   Google Scholar
• Gruenenthal GmbH, Germany. WO2007045462; 2007
   Google Scholar
• Levine JD, Alessandri-Haber N. Trp channels: targets for the relief of pain. Biochim Biophys Acta Mol Basis Dis 2007;1772:989-1003
   PubMed Web of Science ®Google Scholar
• Mandadi S, Roufogalis BD. Thermotrp channels in nociceptors: taking a lead from capsaicin receptor Trpv1. Curr Neuropharmacol 2008;6:21-38
   PubMed Web of Science ®Google Scholar
• Hydra Biosciences, Inc., USA. Application. WO WO2007-US201952008033564; 2008
   Google Scholar
• Hydra Biosciences, Inc., USA). Application. WO WO2006-US42930 2007056124; 2007
   Google Scholar
• Hydra Biosciences, Inc., USA. Application. WO WO2006-US179952006122156; 2006
   Google Scholar
• Chen J, Lake MR, Sabet RS, et al. Utility of large-scale transiently transfected cells for cell-based high-throughput screens to identify transient receptor potential channel A1 (Trpa1) antagonists. J Biomol Screen 2007;12:61-9
   PubMed Web of Science ®Google Scholar
• Hydra Biosciences, Inc., USA. Application. WO WO2006-US492442007073505; 2007
   Google Scholar
• Bayer Healthcare AG, Germany. Application. WO WO2007-EP192 2007080109; 2007
   Google Scholar
• Bayer Healthcare AG, Germany. Application. WO WO2006-EP72972007017092; 2007
   Google Scholar
• Bayer Healthcare AG, Germany. Application. WO WO2006-EP73002007017094; 2007
   Google Scholar
• Bayer Healthcare AG. Germany. Application. WO WO2005-EP109512006040136; 2006
   Google Scholar
• Bayer Healthcare AG. Germany. Application. WO WO2006-EP72982007017093; 2007
   Google Scholar
• Janssen Pharmaceutica NV, Belg. Application. WO WO2007-US685662007134107; 2007
   Google Scholar
• Kennedy JD. Neuropathic pain: molecular complexity underlies continuing unmet medical need. J Med Chem 2007;50:2547-56
   PubMedGoogle Scholar
• Okuse K. Pain signaling pathways: from cytokines to ion channels. Int J Biochem Cell Biol 2007;39:490-6
   PubMed Web of Science ®Google Scholar
• Priest BT, Kaczorowski GJ. Garcia ML. Ion channel modulators: new targets and new indications for old targets. Curr Opin Drug Discov Dev 2006;9:587-94
   PubMedGoogle Scholar
• Wood JN. Ion channels in analgesia research. Handb Exp Pharmacol 2007;177:329-58
   PubMedGoogle Scholar
• Ocana M, Cendan CM, Cobos EJ, et al. Potassium channels and pain: present realities and future opportunities. Eur J Pharmacol 2004;500:203-19
   PubMed Web of Science ®Google Scholar
• Alves DP, Soares AC, Francischi JN, et al. Additive antinociceptive effects of the combination of diazoxide, an activator of ATP-sensitive K+ channels, and sodium nitroprusside and dibutyryl-CGMP. Eur J Pharmacol 2004;489:59-65
   PubMed Web of Science ®Google Scholar
• Picolo G, Cassola AC, Cury Y. Activation of peripheral ATP-sensitive K+ channels mediates the antinociceptive effect of Crotalus Durissus Terrificus snake venom. Eur J Pharmacol 2003;469:57-64
   PubMedGoogle Scholar
• Antibe Pipeline. 2008. Available from: http://www.antibe-therapeutics.com/Product/ATB-429.aspx
   Google Scholar
• Distrutti E, Sediari L, Mencarelli A, et al. 5-Amino-2-Hydroxybenzoic Acid 4-(5-Thioxo-5h-[1,2]-Dithiol-3-Yl)Phenyl Ester (Atb-429), a Hydrogen Sulfide-Releasing Derivative of Mesalamine, Exerts Antinociceptive Effects in a Model of Postinflammatory Hypersensitivity. J Pharamcol Exp Ther 2006;319:447-58
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutica NV, Belg. WO2006091769; 2006
   Google Scholar
• Janssen Pharmaceutica NV, Belg. WO2006091800; 2006
   Google Scholar
• Blackburn-Munro G, Dalby-Brown W. Kv7 (Kcnq) channel modulators and neuropathic pain. J Med Chem 2007;50:2576-82
   PubMedGoogle Scholar
• Blackburn-Munro G, Dalby-Brown W, Mirza N, et al. Retigabine: chemical synthesis to clinical application. CNS Drug Reviews 2005
   Google Scholar
• Porter RJ, Nohria V, Rundfeldt C. Retigabine. Neurotherapeutics 2007;4:149-54
   PubMed Web of Science ®Google Scholar
• Valeant Pipeline. 2008. Available from: http://www.valeant.com/researchAndDevelopment/pipeline/retigabine.jspf
   Google Scholar
• Dalby-Brown W, Hansen HH, Korsgaard MPG, et al. Kv7 channels: function, pharmacology and channel modulators. Curr Top Med Chem 2006;6:999-1023
   PubMedGoogle Scholar
• Wickenden AD, Roeloffs R, McNaughten-Smith G, Rigdon GC. Kcnq potassium channels: drug targets for the treatment of epilepsy and pain. Expert Opin Ther Patents 2004;14:1-13
   Google Scholar
• Nardi Aao S-P. Acrylamides as potassium channel openers. Expert Opin Ther Patents 2007;17:1215-26
   Google Scholar
• Xiong Q, Gao Z, Wang W, LI M. Activation of Kv7 (Kcnq) voltage-gated potassium channels by synthetic compounds. Trends Pharmacol Sci 2008;29:99-107
   PubMedGoogle Scholar
• Wickenden AD, McNaughten-Smith G, Roeloffs R, et al. Ica-27243: a novel, potent and selective Kcnq2/3 potassium channel activator. Soc Neurosci Abst 2005:153.113
   Google Scholar
• Wu Y-J, Boissard CG, Greco C, et al. (S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]-3-phenylacrylamide: an orally bioavailable Kcnq2 opener with significant activity in a cortical spreading depression model of migraine. J Med Chem 2003;46:3197-200
   PubMed Web of Science ®Google Scholar
• Christos TE, McNaughton-Smith G, Atkinson RN, et al. Discovery and biological evaluation of novel 2-acetamido-indoles as potent and selective openers of Kv7/Kcnq potassium channels. Abstracts of Papers, 234th ACS National Meeting; 19 – 23 August 2007; Boston MA, USA, MEDI-150
   Google Scholar
• H. Lundbeck A/S, Den. US2007066612; 2007
   Google Scholar
• H. Lundbeck A/S, Den. WO2006092143; 2006
   Google Scholar
• H. Lundbeck A/S, Den. WO2006029623; 2006
   Google Scholar
• Neurosearch A/S, Den. WO2007057447; 2007
   Google Scholar
• Neurosearch A/S, Den. WO2007104717; 2007
   Google Scholar
• Gruenenthal GmbH, Germany. WO2006122800; 2006
   Google Scholar
• The Johns Hopkins University, USA. WO2007087424; 2007
   Google Scholar
• Liegeois J-F, Mercier F, Graulich A, et al. Modulation of small conductance calcium-activated potassium (Sk) Channels: a new challenge in medicinal chemistry. Curr Med Chem 2003;10:625-47
   PubMed Web of Science ®Google Scholar
• Neurosearch A/S, Den. WO2006136580; 2006
   Google Scholar
• Neurosearch A/S, Den. WO2007042571; 2007
   Google Scholar
• Neurosearch A/S, Den. WO2007110363; 2007
   Google Scholar
• Neurosearch A/S, Den. WO2006074991; 2006
   Google Scholar
• Neurosearch A/S, Den. WO2006097441; 2006
   Google Scholar
• Neurosearch A/S, Den. WO2006100212; 2006
   Google Scholar
• Neurosearch A/S, Den. WO2007071632; 2007
   Google Scholar
• Cummins TR, Rush AM. Expert Rev Neurother 2007;7:1597-612
   PubMedGoogle Scholar
• Hargus NJ, Patel MK. Voltage-gated Na+ channels in neuropathic pain. Expert Opin Investig Drugs 2007;16:635-46
   PubMed Web of Science ®Google Scholar
• Krafte Dsab AW. Sodium channels and nociception: recent concepts and therapeutic opportunities. Curr Opin Pharmacol 2008;8:50-6
   PubMedGoogle Scholar
• Priest Btak GJ. Blocking sodium channels to treat neuropathic pain. Expert Opin Ther Targets 2007;11:291-306
   PubMedGoogle Scholar
• Silos-Santiago I. The role of tetrodotoxin-resistant sodium channels in pain states: are they the next target for analgesic drugs? Curr Opin Investig Drugs 2008;9:83-9
   PubMedGoogle Scholar
• Hagen NA, Fisher KM, Lapointe B, et al. An open-label, multi-dose efficacy and safety study of intramuscular tetrodotoxin in patients with severe cancer-related pain. J Pain Symptom Manage 2007;34:171-82
   PubMed Web of Science ®Google Scholar
• Kyle Djai VI. Sodium channel blockers. J Med Chem 2007;50:2583-8
   PubMedGoogle Scholar
• Sharp D. Novel pain relief via marine snails. Lancet 2005;366:439-40
   PubMedGoogle Scholar
• Bulaj G, Zhang M-M, Green BR, et al. Synthetic Mo-conotoxin Mrvib blocks Ttx-resistant sodium channel Nav1.8 and has a long-lasting analgesic activity. Biochemistry 2006;45:7404-14
   PubMed Web of Science ®Google Scholar
• Kort ME, Drizin I, Gregg RJ, et al. Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain. J Med Chem 2008;51:407-16
   PubMed Web of Science ®Google Scholar
• Hoyt SB, London C, Ok H, et al. Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain. Bioorg Med Chem Lett 2007;17:6172-7
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc., USA. WO2007145922; 2007
   Google Scholar
• Williams BS, Felix JP, Priest BT, et al. Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7. Biochememistry 2007;46:14693-703
   PubMed Web of Science ®Google Scholar
• Marrion B. Novel sodium channel blockers for the treatment of neuropathic pain. Ann Rep Med Chem 2006;41:59-73
   Google Scholar
• Tarnawa I, Bolcskei H, Kocsis P. Blockers of voltage-gated sodium channels for the treatment of central nervous system diseases. Recent Patents CNS Drug Discov 2007;2:57-78
   PubMedGoogle Scholar
• Vertex Pharmaceuticals Incorporated, USA. WO2006119451; 2006
   Google Scholar
• Vertex Pharmaceuticals Incorporated, USA. WO2006028904; 2006
   Google Scholar
• Vertex Pharmaceuticals. US2006217377; 2006
   Google Scholar
• Vertex Pharmaceuticals Incorporated, USA. WO2006119390; 2006
   Google Scholar
• Vertex Pharmaceuticals Incorporated, USA. WO2006127329; 2006
   Google Scholar
• Vertex Pharmaceuticals Incorporated, USA. WO2007058989; 2007
   Google Scholar
• Vertex Pharmaceuticals Incorporated, USA. WO2006133459; 2006
   Google Scholar
• Vertex Pharmaceuticals Incorporated, USA. WO2006124744; 2006
   Google Scholar
• Vertex Pharmaceuticals Incorporated, USA. WO2006122014; 2006
   Google Scholar
• Vertex Pharmaceuticals, Inc., USA. WO2007047474; 2007
   Google Scholar
• Vertex Pharmaceuticals Incorporated, USA. WO2007050522; 2007
   Google Scholar
• Vertex Pharmaceuticals, Inc., USA. WO2007030618; 2007
   Google Scholar
• Vertex Pharmaceuticals Incorporated, USA. WO2007075895; 2007
   Google Scholar
• Vertex Pharmaceuticals Incorporated, USA. WO2006124865; 2006
   Google Scholar
• Vertex Pharmaceuticals Incorporated, USA. WO2006130493; 2006
   Google Scholar
• Pfizer Limited, UK. WO2007052123; 2007
   Google Scholar
• Icagen, Inc., USA. WO2007056099; 2007
   Google Scholar
• Cao Y-Q. Voltage-gated calcium channels and pain. Pain 2006;126:5-9
   PubMed Web of Science ®Google Scholar
• Yaksh TL. Calcium channels as therapeutic targets in neuropathic pain. J Pain 2006;7(Suppl 1):S13-30
   PubMed Web of Science ®Google Scholar
• Eisenberg E, River Y, Shifrin A, Krivoy N. Antiepileptic drugs in the treatment of neuropathic pain. Drugs 2007;67:1265-89
   PubMed Web of Science ®Google Scholar
• Cheng, J-Kac L-C. Mechanisms of the antinociceptive action of gabapentin. J Pharamacol Sci 2006;100:471-86
   PubMed Web of Science ®Google Scholar
• Gajraj NM. Pregabalin: its pharmacology and use in pain management. Analg Anesth 2007;105:1805-15
   PubMed Web of Science ®Google Scholar
• Field MJ, Li Z, Schwarz JB. Ca2+ channel A2d ligands for the treatment of neuropathic pain. J Med Chem 2007;50:2569-757
   PubMed Web of Science ®Google Scholar
• Lynch SS, Cheng CM, Yee JL. Intrathecal ziconotide for refractory chronic pain. Ann Pharmacother 2006;40:1293-300
   PubMedGoogle Scholar
• Available from: http://www.neuromed.com/news/pressr.php?nr=6&txt=&pyear=2007. Neuromed Press Release, 2008
   Google Scholar
• Thompson Pharma® Website, 2008. Available from: http://thompson-pharma.com
   Google Scholar
• Schroeder CI, Doering CJ, Zamponi GW, Lewis RJ. N-type calcium channel blockers: novel therapeutics for the treatment of pain. Med Chem 2006;2:535-43
   PubMedGoogle Scholar
• Yamamoto T, Niwa S, Iwayama S, et al. Discovery, structure-activity relationship study and oral analgesic efficacy of cyprohetadine derivatives possessing N-type calcium channel inhibitory activity. Bioorg Med Chem 2006;14:5333-9
   PubMedGoogle Scholar
• Merck & Co., Inc., USA. WO2007075524; 2007
   Google Scholar
• Merck & Co., Inc., USA. WO2007084394; 2007
   Google Scholar
• Pfizer Japan, Inc., Japan, Pfizer, Inc. WO2007125398; 2007
   Google Scholar
• Ionix Pharmaceuticals Limited, UK. WO2005068448; 2005
   Google Scholar
• Neuromed Pharmaceuticals Ltd., Can. WO2007118323; 2007
   Google Scholar
• Neuromed Pharmaceuticals Ltd., Can. WO2007071035; 2007
   Google Scholar
• Neuromed Pharmaceuticals Ltd., Can. WO2007137417; 2007
   Google Scholar
• Euro-Celtique SA, Luxembourg. WO2007110449; 2007
   Google Scholar
• Euro-Celtique SA, Luxembourg. WO2007118853; 2007
   Google Scholar
• Euro-Celtique SA, Luxembourg, Shionogi & Co., Ltd. WO2007118854; 2007
   Google Scholar
• Shionogi & Co., Ltd., Japan, Euro-Celtique SA. WO2008008398; 2008
   Google Scholar
• Euro-Celtique SA, Luxembourg. WO2007085357; 2007
   Google Scholar
• Lory Pac J. Towards the discovery of novel T-type calcium channel blockers. Expert Opin Ther Targets 2007;11:717-22
   PubMedGoogle Scholar
• Nelson MT, Todorovic SM, Perez-Reyes E. The role of T-type calcium channels in epilepsy and pain. Curr Pharm Des 2006;12:2189-97
   PubMed Web of Science ®Google Scholar
• Jo MN, Seo HJ, Kim Y, et al. Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem 2007;15:365-73
   PubMed Web of Science ®Google Scholar
• Doddareddy MR, Choo H, Cho YS, et al. 3d pharmacophore based virtual screening of T-type calcium channel blockers. Bioorg Med Chem 2007;15:1091-105
   PubMed Web of Science ®Google Scholar
• Euro-Celtique SA, Luxembourg. WO2007028638; 2007
   Google Scholar
• Korea Institute of Science and Technology, S. Korea. WO2008018655; 2008
   Google Scholar
• Korea Institute of Science and Technology, S. Korea. EP1757590; 2007
   Google Scholar
• Korea Institute of Science and Technology, S. Korea. KR758317; 2007
   Google Scholar
• Merck & Co., Inc., USA. WO2007120729; 2007
   Google Scholar
• Merck & Co., Inc., USA. WO2007002361; 2007
   Google Scholar
• Merck & Co., Inc., USA. WO2007002884; 2007
   Google Scholar
• Icagen, Inc., USA. WO2007073497; 2007
   Google Scholar
• Icagen, Inc., USA. WO2007075852; 2007
   Google Scholar
• Wemmie J, Price MP, Welsh MJ. Acid-sensing ion channels: advances, questions and therapeutic opportunities. Trends Neurosci 2006;29:578-86
   PubMed Web of Science ®Google Scholar
• Xiong Z-G, Pignataro G, Li M, et al. Acid-sensing ion channels (Asics) as pharmacological targets for neurodegenerative diseases. Curr Opin Pharmacol 2008;8:25-32
   PubMed Web of Science ®Google Scholar
• Ugawa S, Ueda T, Ishida Y, et al. Amiloride-blockable acid-sensing ion channels are leading acid sensors expressed in human nociceptors. J Clin Invest 2002;110:1185-90
   PubMed Web of Science ®Google Scholar
• Sluka KA, Price MP, Breese NM, et al. Chronic hyperalgesia induced by repeated acid injections in muscle is abolished by the loss of Asic3, but not Asic1. Pain 2003;106:229-39
   PubMed Web of Science ®Google Scholar
• Jones NG, Slater R, Cadiou H, et al. Acid-induced pain and its modulation in humans. J Neurosci 2004;24:10974-9
   PubMed Web of Science ®Google Scholar
• Page AJ, Brierly SM, Martin CM, et al. Acid sensing ion channels 2 and 3 are required fo inhibition of visceral nociceptors by benzamil. Pain 2007;133:150-60
   PubMedGoogle Scholar
• Dube GR, Lehto SG, Breese NM, et al. Electrophydiological and in vivo characterization of a-317567, a novel blocker of acid sensing ion channels. Pain 2005;117:88-96
   PubMed Web of Science ®Google Scholar
• Painceptor Pharma Corp., Can., Neurosearch A/S. WO2006038070; 2006
   Google Scholar
• Painceptor Pharma Corporation, Can. WO2007059608; 2007
   Google Scholar
• Painceptor Pharma Corporation, Can. WO2007115409; 2007
   Google Scholar
• Painceptor Pharma Corporation, Can. WO2007071055; 2007
   Google Scholar
• Eli Lilly and Company, USA. WO2004017977; 2004
   Google Scholar
• Eli Lilly and Company, USA. WO2004018441; 2004
   Google Scholar
• Eli Lilly and Company, USA. WO2004043931; 2004
   Google Scholar
• Sepracor, Inc., USA. WO2002046156; 2002
   Google Scholar
• Pfizer, Inc., USA. US2005096327; 2005
   Google Scholar
• Mokrosz JL, Duszynska B, Charakchieva-Minol S, et al. Structure-activity relationship studies of CNS agents. Part 29. N-methylpiperazino-substituted derivatives of quinazoline, phthalazine and quinoline as novel A1, 5-Ht1a and 5-Ht2a receptor ligands. Eur J Med Chem 1996;31:973-80
   Google Scholar
• Pfizer Products, Inc., USA. WO2007031828; 2007
   Google Scholar
• Pfizer, Inc., USA. US2005014848; 2005
   Google Scholar
• Pfizer Inc., USA. US2005009927; 2005
   Google Scholar
• Pfizer, Inc., USA. US2007142389; 2007
   Google Scholar
• Wyeth, John, Brother Ltd., USA. WO2005037279; 2005
   Google Scholar
• Wyeth, John, Brother Ltd., USA. US2007015828; 2007
   Google Scholar
• Mahaney PE, Trybulski EJ, Stack G, et al. Sar of the cycloalkanol ethylamine scaffold: N-substituted piperazine reuptake inhibitors. Abstracts of Papers, 234th ACS National Meeting; 19 – 23 August 2007; Boston, MA, USA, MEDI-416
   Google Scholar
• Wyeth John, Brother Ltd., USA. US2005222148; 2005
   Google Scholar
• Mahaney PE, At VU, McComas CC, et al. Synthesis and activity of a new class of dual acting norepinephrine and serotonin reuptake inhibitors: 3-(1h-indol-1-yl)-3-arylpropan-1-amines. Bioorg Med Chem 2006;14:8455-66
   PubMedGoogle Scholar
• Lundbeck H A/S, Denmark. WO2006007843; 2006
   Google Scholar
• Organon NV, Neth. US2007185156; 2007
   Google Scholar
• Warner-Lambert Company LLC, USA. US2005245519; 2005
   Google Scholar
• Warner-Lambert Company LLC, USA. WO2006056873; 2006
   Google Scholar
• Bristol-Myers Squibb Company. WO2006020049; 2006
   Google Scholar
• Nielsen CK, Lewis RJ, Alewood D, et al. Anti-allodynic efficacy of the C-conopeptide, Xen2174, in rats with neuropathic pain. Pain 2005;118:112-24
   PubMed Web of Science ®Google Scholar
• Obata H, Conklin D, Eisenach JC. Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats. Pain 2005;113:271-6
   PubMedGoogle Scholar
• Lever IJ, Rice ASC. Cannabanoids and pain. Handb Exp Pharmacol 2007;177(Analgesia):265-306
   Google Scholar
• Whiteside GT, Lee GP, Valenzano KJ. The role of the cannabinoid Cb2 receptor in pain transmission and therapeutic potential of small molecule Cb2 receptor agonists. Curr Med Chem 2007;14:917-36
   PubMed Web of Science ®Google Scholar
• Smith PF. Will medicinal cannabanoids prove to be useful clinically? Curr Drug Ther 2007;2:143-50
   Google Scholar
• Russo EB, Guy GW, Robson PJ. Cannabis, pain and sleep: lessons from therapeutic clinical trials of Sativexâ, a cannabis-based medicine. Chem Biodivers 2007;4:1729-43
   PubMed Web of Science ®Google Scholar
• Ross RA, Brockie HC, Stevenson LA, et al. Agonist-inverse agonist characterization at Cb1 and Cb2 cannabinoid receptors of L759663, L759656 and Am630. Br J Pharamcol 1999;126:655-72
   Google Scholar
• Glaxo Group Limited, UK. WO2004018433; 2004
   Google Scholar
• Chen Y, Hitchcock SA. Targeting cananbinoid agonists for inflammatory and neuropathic pain. Expert Opin Investig Drugs 2007;16:951-65
   PubMedGoogle Scholar
• Hogenauer EK. Latest advances in the cannabanoids. Expert Opin Ther Patents 2007;17:1457-76
   Web of Science ®Google Scholar
• Bingham B, Jones PG, Uveges A, et al. Species-specific phamracological effects of the cannabinoid receptor 2 (Cb2) selective ligand Am1241 and its resolved enantiomers. Brit J Pharmacol 2007;1061-70
   PubMedGoogle Scholar
• Gonsiorek W, Lunn CA, Fan X, et al. Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (Cb2) in rodents and primates. Br J Pharmacol 2007;151:1262-71
   PubMed Web of Science ®Google Scholar
• Papahatjis DP, Nahmias VR, Nikas SP, et al. C1′-cycloalkyl side chain pharmacophore in tetrahydrocannabinols. J Med Chem 2007;50:4048-60
   PubMed Web of Science ®Google Scholar
• Khanolkar AD, Lu D, Ibrahim M, et al. Cannabilactones: a novel class of Cb2 selective agonists with peripheral analgesic activity. J Med Chem 2007;50:6493-500
   PubMed Web of Science ®Google Scholar
• Durdagi S, Kapou A, Kourouli T, et al. The application of 3d-Qsar studies for novel cannabinoid ligands substituted at the C1′ position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors Cb1 and Cb2. J Med Chem 2007;50:2875-85
   PubMedGoogle Scholar
• Worm K, Zhou QJ, Stably GJ, et al. Biaryl cannabinoid mimetics – synthesis and structure-activity relationship. Bioorg Med Chem Lett 2007;17:3652-6
   PubMedGoogle Scholar
• Ohta H, Ishizaka T, Tatsuzuki M, et al. N-alkylidenearylcarboxamides as new potent and selective Cb2 cannabinoid receptor agonists with good oral bioavailability. Bioorg Med Chem Lett 2007;17:6299-304
   PubMedGoogle Scholar
• Minutolo F, Cascio MG, Carboni I, et al. Metabolically labile cannabinoid esters: a ‘Soft Drug’ approach for the development of cannabinoid-based therapeutic drugs. Bioorg Med Chem Lett 2007;17:4878-81
   PubMedGoogle Scholar
• Stern E, Muccioli GG, Millit R, et al. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new Cb2 cannabinoid receptors agonists: synthesis pharmacological properties and molecular modeling. J Med Chem 2006;49:70-9
   PubMed Web of Science ®Google Scholar
• Stern E, Muccioli GG, Bosier B, et al. Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent Cb2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality. J Med Chem 2007;50:5471-84
   PubMed Web of Science ®Google Scholar
• Manera C, Cascio MG, Benetti V, et al. New 1,8-naphthyridine and quinoline derivatives as Cb2 selective agonists. Bioorg Med Chem Lett 2007;17:6505-10
   PubMed Web of Science ®Google Scholar
• Lavey BJ, Kozlowski JA, Shankar BB, et al. Optimization of triaryl bis-sulfones as cannabinoid-2 receptor ligands. Bioorg Med Chem Lett 2007;17:3760-4
   PubMed Web of Science ®Google Scholar
• Kai H, Morioka Y, Murashi T, et al. 2-Arylimino-5,6-dihydro-4h-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 1. Discovery of Cb2 receptor selective compounds. Bioorg Med Chem Lett 2007;17:4030-4
   PubMed Web of Science ®Google Scholar
• Kai H, Morioka Y, Tomida M, et al. 2-Arylimino-5,6-dihydro-4h-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2. Orally bioavailable compounds. Bioorg Med Chem Lett 2007;17:3925-9
   PubMed Web of Science ®Google Scholar
• Ohta H, Ishizaka T, Yoshinaga M, et al. Sulfonamide derivatives as new potent and selective Cb2 cannabinoid receptor agonists. Bioorg Med Chem Lett 2007:17:5133-5
   PubMedGoogle Scholar
• Ohta H, Ishizaka T, Tatsuzuki M, et al. N-alkylidinecarboxamides as new potent and selective Cb2 cannabinoid receptor agonists with good oral bioavailability. Bioorg Med Chem Lett 2007;17:6299-304
   PubMedGoogle Scholar
• Page D, Yang H, Brown W, et al. New 1,2,3,4-tetrahydropyrrolo[3,4-B]indole derivatives as selectivite Cb2 receptor agonists. Bioorg Med Chem Lett 2007;17:6183-7
   PubMedGoogle Scholar
• Boehringer Ingelheim Pharma GmbH. & Co. K-G. WO2007118041; 2007
   Google Scholar
• Boehringer Ingelheim Pharma GmbH. & Co. K-G. WO2007070760; 2007
   Google Scholar
• The University of Connecticut. US2007243134; 2007
   Google Scholar
• The University of Connecticut. WO2002060447; 2002
   Google Scholar
• Abbott Laboratories, USA. WO2007140439; 2007
   Google Scholar
• Solvay Pharmaceuticals GmbH, Germany. WO2007125049; 2007
   Google Scholar